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Abstract
In phase I clinical trials, the standard ‘3+3’ design has passed the test of time and survived
various sample size adjustments, or other dose-escalation dynamics. The objective of this study
is to provide a probabilistic support for analyzing the heuristic performance of the ‘3+3’ design.
Our likelihood method is based on the evidential paradigm that uses the likelihood ratio to
measure the strength of statistical evidence for one simple hypothesis over the other. We
compute the operating characteristics and compare the behavior of the standard algorithm under
different hypotheses, levels of evidence, and true (or best guessed) toxicity rates. Given observed
toxicities per dose level, the likelihood-ratio is evaluated according to a certain k threshold (level
of evidence). Under an assumed true toxicity scenario the following statistical characteristics are
computed and compared: i) probability of weak evidence, ii) probability of favoring H1 under

H1 (analogous to 1-α), iii) probability of favoring H 2 under H 2 (analogous to 1-β). This
likelihood method allows consistent inferences to be made and evidence to be quantified
regardless of cohort size. Moreover, this approach can be extended and used in phase I designs
for identifying the highest acceptably safe dose and is akin to the sequential probability ratio test.

Keywords: phase I clinical trials, standard algorithm, likelihood method, evidential paradigm.

1. Introduction
Phase I trials in which new drugs or drug combinations are administered to human patients for
the first time are conducted to select a dose to be used in subsequent trials. In oncology and
other life threatening diseases, dose-finding studies most often aim to identify the maximum
tolerated dose (MTD) defined as a dose whose probability of toxicity is closest to some
acceptable, prespecified target, also known as the dose limiting toxicity (DLT) rate. The primary
outcome for these trials is usually a binary indicator of the presence or absence of a DLT, with
the underlying assumption that the probability of toxicity is a non-decreasing function of dose.
Despite considerable efforts since 1990 to encourage the use of model-based dose-finding
designs, such as the Continual Reassessment Method (CRM) and its variants (see, e.g.,
O’Quigley, Pepe, and Fisher, 1990; Piantadosi, Fisher, and Grossman, 1998; Goodman, Zahurak,
and Piantadosi, 1995; Yuan, Chappell, and Bailey, 2007; Cheung and Chappell, 2000; Moller,
1995), and Escalation with Overdose Control (EWOC) (Babb, Rogatko, and Zacks, 1998;
Tighiouart, Rogatko, and Babb, 2005), the most common approach for dose-finding remains an
‘Up-and-Down’ algorithm. These methods assign patients sequentially based on prespecified
decision rules. They are easy to implement, requiring no cumbersome calculations (before or
during the trial) and no pre-specification of the underlying dose-toxicity model. Currently, there
are a multitude of ad-hoc ‘Up-and-Down’ methods with the majority falling within the range of
‘A+B’ designs (Ivanova, 2006; Lin and Shih, 2001).
The most common ‘A+B’ design is the ‘3+3’ algorithm, planned to sample around the
33rd percentile (Storer, 1989). The popularity of the design is due mainly to its practical
simplicity. For a limited number of dose levels ( ≤ 5 ), the ‘3+3’ showed comparable properties to
the CRM in terms of number of patients treated to reach the MTD (Iasonos et al., 2008). A more

recent study argued the utility of the ‘3+3’ in practice by demonstrating (via simulations) that the
standard algorithm was a better method when none of the investigational dose levels was close to
the true MTD (Ji and Wang, 2013). An important limitation is its short memory (i.e., the decision
rules are based on the outcomes from the most recent cohort of patients). Another drawback
consists of a slow dose escalation, leading to treatment of an excessive number of patients at
dose levels less likely to be efficacious (O’Quigley et al., 1990; Goodman et al., 1995; Storer,
1989). After evaluating the ‘3+3’ operating characteristics, Lin and Shih (2001) concluded that
the design does not have a fixed DLT at the MTD, such as 33%, and that it targets doses with a
DLT rate between 16%-27% (Ivanova, 2006). Reiner, Paoletti, and O’Quigley (1999) concluded
that this design has high error rates and frequently leads to incorrect decisions, e.g. the
probability of recommending the correct MTD at the end of the trial never exceeds 44% and is
actually closer to 30%. Also, estimators of the MTD are based on information collected from
only six patients, and these tend to be biased or inconsistent (Storer, 1989; Brownlee, Hodges,
and Rosenblatt, 1953; O’Quigley, 2006). Due to the empirical nature, the ‘3+3’ has limited
capabilities of describing and accounting for uncertainties in the observed data. However, despite
the limited power of generality and the rigid design, 98% of the dose-finding cancer trials
conducted between 1991 and 2006 implemented variations of the standard ‘Up-and-Down’
method (Rogatko et al., 2007).
Given the intuitive and transparent implementation, the ‘3+3’ design continues to be
clinicians’ most popular choice for phase I trials. The objective of this study is not to argue the
use of the standard ‘3+3’ design, but to provide a method for describing the statistical properties
of its heuristic performance. Our likelihood-based method can be used to compute the operating
characteristics and compare the behavior of the standard design under different hypotheses,

levels of evidence, and true (or best guessed) toxicity rates. The method is based on the
evidential paradigm that uses observed data to compute the likelihood ratio (LR), and then
classify the level of evidence as: 1) weak evidence or 2) strong evidence in favor of one of the
proposed hypotheses (denoted here as H 1 and H 2 ). This approach uses only the observed data as
evidence for one hypothesis versus the other and provides an objective measure of the strength of
this evidence. First, we present the evidential paradigm. Next, we apply our evidential approach
to the ‘3+3’ design and compute the operating characteristics under a wide range of true
toxicities, four sets of simple hypotheses, and three levels of evidence providing guidance for the
performance of the ‘3+3’ based on acceptable and unacceptable DLT rates. Last, we present
results from a simulation study, draw conclusions, and give some suggestions for extending the
method.

2. The evidential paradigm
Forster (2006) stated in one of his articles that “contemporary statistics is divided into three
camps: classical Neyman-Pearson statistics, Bayesianism, and third, but not last, Likelihoodism.”
All three approaches are structured upon the likelihood ratio (LR) and the specification of a set
of hypotheses, where usually the alternative represents the minimum clinically important
difference. Likelihoodism is another school of thought of evidential statistics that uses databased evidence to quantify the relative support for one model versus the other. The concept was
first introduced by Hacking (1965) by stating the formal expression of the Law of Likelihood
and using the likelihood ratio (LR) for comparing two simple hypotheses, such as H1 : θ = θ1 and

H 2 : θ = θ2 for a parameter θ , under the assumption that a background model is true. The
evidential paradigm provides the LR of the two hypotheses, LR = L(θ2 ; x) / L(θ1 ; x) as an

objective measure of the strength of evidence. Strong evidence supporting θ 2 over θ1 exists if for
a large k, LR ≥ k . Similarly, strong evidence supporting θ1 over θ 2 exists if LR ≤ 1 / k . Weak
evidence occurs when 1 / k < LR < k , with no strong support for either one of the hypotheses.
Royall (1997) and Blume (2002) established a correspondence between the values of k and type I
and II errors. They proposed benchmarks of 8 and 32, representing “weak” ( 1 < LR < 8 ), “fairly
strong” ( 8 < LR < 32 ), and “strong” ( LR > 32 ) levels of evidence. Initially, these benchmarks
were derived to provide levels of evidence similar to error thresholds of α = 0.05 and β = 0.20 ,
in the context of a phase III trial. In phase I trials, controlling these error rates is not as stringent.
However, one should be concerned with the small number of subjects enrolled (usually < 25 ).
The limited amount of accumulated information (evidence) seldom generates likelihood ratios
less than 8. Therefore, a value of k = 8 may be considered an unrealistic threshold for
quantifying evidence in phase I studies.

Error probabilities in the evidential paradigm
A key aspect of evaluating study designs is computing the operating characteristics, such as the
frequency with which the study will produce misleading or weak evidence. Ideally, the
probabilities measuring how often evidence of a particular type will be observed should not
affect the strength of statistical evidence quantified by the likelihood-ratio. For example, in the
evidential paradigm, the probability of observing misleading evidence is a function of the fixed k
(strength of evidence) and sample size n . On the contrary, the analogous type I error from
hypothesis testing is fixed at α and the strength of evidence at which the test rejects, kα , n ,
depends on α and n . In this situation, it is often possible that two tests that reject at the same α
level could have different strengths of evidence.

The evidential paradigm defines misleading evidence as strong evidence in favor of the
incorrect hypothesis, calculated under a true hypothesis. Given two simple hypotheses H1 : θ = θ1
and H 2 : θ = θ 2 , for x = ( x1 , x2 ,..., xn ) i.i.d. observations, the probabilities of observing
misleading evidence can be calculated as follows:

⎛ L(θ 2 ; x)
⎞
M 1 (n, k ) = P1 ⎜
≥ k | H1 true ⎟
⎝ L(θ1 ; x)
⎠
⎛ L(θ 2 ; x) 1
⎞
M 2 (n, k ) = P2 ⎜
≤ | H 2 true ⎟ , k fixed over n.
⎝ L(θ1 ; x) k
⎠
Following the definition above, M 1 (n, k ) represents the evidential analog to a type I error. It has
been shown that for any fixed sample size n and any pair of probability distributions, the
probability of misleading evidence under the true hypothesis satisfies the universal bound
(Royall, 1997; Royall, 2000). That is, the probability that accumulated observations will
represent strong evidence supporting the false hypothesis over the true hypothesis cannot exceed

1/ k (with a similar bound under H 2 ):

⎛ L(θ 2 ; x)
⎞ 1
M1 (n, k ) = P1 ⎜
≥ k | H1 true ⎟ ≤ .
⎝ L(θ1; x)
⎠ k
This feature is extremely useful in sequential trials, where multiple looks at the data produce an
inflation of the type I error. In the evidential approach, the probability of observing misleading
evidence increases with each look, but it still remains bounded (Robbins, 1970).
The second error probability - probability of observing weak evidence - is defined as the
probability that an experiment will not produce strong evidence for either hypothesis relative to
the other, calculated under each true hypothesis:

⎛ 1 L(θ 2 ; x)
⎞
W1 (n, k ) = P1 ⎜ <
< k | H1 true ⎟
⎝ k L(θ1 ; x)
⎠
⎛ 1 L(θ 2 ; x)
⎞
W2 (n, k ) = P2 ⎜ <
< k | H 2 true ⎟ , k fixed over n.
⎝ k L(θ1; x)
⎠
Similarly, W2 (n, k ) represents the evidential analog to the type II error. In his tutorial, Blume
(2002) emphasizes the difference in definition and behavior between the probabilities of
misleading and weak evidence and the classical type I and type II errors. Furthermore, in the
context of experimental design, he shows that both probabilities of misleading and weak
evidence converge to zero as the sample size increases.

3. Methods
Consider the general setting of the ‘3+3’ design that uses cohorts of 3 patients with the ultimate
goal of finding the MTD. The algorithm begins with 3 patients treated at the first (lowest) dose
level. If 0 out of 3 patients experiences a DLT, the dose will be escalated. If 2 out of 3 patients
have a DLT, the dose will be de-escalated. If 1 out of 3 patients has a DLT, 3 more patients will
be enrolled at the same dose level, and if no additional patients experience a DLT, then the dose
will be escalated. Otherwise (i.e., 2 or more DLTs at a dose level) de-escalation will occur. The
algorithm continues until at least two patients among a cohort of 3 to 6 patients experience a
DLT or the maximum dose level specified in the trial is reached. The MTD is defined as the dose
level just below the toxic dose level which will have either 0 or 1 DLTs among 3 or 6 patients.
With a maximum of 6 patients per dose, the precision with which the true DLT rate can
be estimated at each dose is very poor. With such a high level of uncertainty in the true DLT rate
at the defined MTD, the safety profile cannot sufficiently be established. In order to improve the
MTD estimation, the Accelerated Titration design fits a logistic model to all data after the trial

completion and generates a point estimate (with confidence interval) for the MTD (Simon et al.,
1997). Even though the median MTD is similar to that derived from traditional phase I studies,
the precision of the MTD estimate is still limited because of the small sample size.
For those who choose to use the ‘3+3’ design, we offer statistically derived properties for
describing its behavior under different scenarios and for quantifying the levels of evidence. Our
likelihood method can be used either in the preparatory phase of the trial for determining
whether or not the ‘3+3’ can provide a dose with an acceptable DLT rate, or after completion, for
evaluating the operating characteristics at each dose level. As discussed later, it can also provide
guiding principles for ascertaining toxicity of a dose when the cohort size is beyond the standard
number of 3 or 6 patients used by the ‘3+3’ algorithm.
In our proposed method, all the statistical properties are calculated per each dose level,
based on observed toxicities. Let d j , j = 1, 2,..., K , be the set of ordered dose levels, and y j be
the corresponding number of observed toxicities at the jth dose. Let n j be the number of patients
per dose with a maximum of 6. For each dose, let P( DLT | dose = d j ) = p j , the true probability
of observing a DLT at the jth dose. Consider the following where P( DLT | dose = d j ) = p1 and

P ( DLT | dose = d j ) = p2 are the two hypothesized DLT rates at dose d j :

H 1j : p j = p1 (unsafe dose)
H 2j : p j = p2 (acceptable dose)
For a choice of p1 and p2 established a priori, we calculate the likelihood-ratio (LR) for each
dose:
yj

⎛ p ⎞ ⎛ 1 − p2 ⎞
LR j = ⎜ 2 ⎟ ⎜
⎟
⎝ p1 ⎠ ⎝ 1 − p1 ⎠

nj −y j

, j = 1, 2,..., K

Using the estimated likelihood-ratio and a certain benchmark k, we interpret the strength of
evidence as follows:
i.

Weak evidence (supporting neither hypothesis), if

ii.

Evidence in favor of H 2 , if LR j ≥ k

iii.

Evidence in favor of H 1 , if LR j ≤

1
< LR j < k
k

1
k

As mentioned previously, benchmark values of k = 8 and 32 have been proposed to distinguish
between weak, moderate, and strong evidence (Royall, 1997; Blume, 2002). In the case of ‘3+3’,
we know that a maximum sample size of 6 patients can produce only relatively modest
likelihood ratios (except when there is a very large difference between p1 and p2 , such
as p1 = 0.60 , p2 = 0.10 ). Thus, selecting a k greater than 8 is not feasible for such small cohort
sizes. After toxicity responses at a certain dose level have been observed, the strength of
evidence for one hypothesis over the other is quantified and a decision is made of “too toxic”,
“safe” or “weak evidence”. The last category can be subject to interpretability. We regard the
weak evidence as not having enough information to conclude toxicity, and choose to combine it
with the evidence of concluding that the dose is safe. In other words, a dose is considered safe
until there is sufficient evidence to conclude that it is too toxic.
In order to assess the ‘3+3’ behavior in the context of likelihood inference, we also
calculate the probabilities of escalation (dose is safe) and non-escalation (dose is unsafe) based
on the algorithmic rules. For any dose d j , let y1j be the count of DLTs in the first cohort of 3
patients, and let y2j be the count of DLTs in the second cohort of 3 patients. Then, y1j and y2j are

two independent binomial random variables, with n j = 3 and P ( DLT | dose = d j ) = p j for

j = 1, 2,..., K . Thus, for any given p j , the following probabilities hold true:

P(escalation | d j ) = P (( y1j = 0) ∪ ( y1j = 1, y2j = 0) )
= P( y1j = 0) + P( y1j = 1) ⋅ P( y2j = 0)
= (1 − p j )3 + 3 p j (1 − p j )5
P(non − escalation | d j ) = 1 − P(escalation | d j )
Simulation set-up
We calculated the operating characteristics of the ‘3+3’design using the likelihood method. For
each dose, H1 ( p1 ) is defined as the unsafe DLT rate, and H 2 ( p2 ) is considered an acceptable
DLT rate. Data were simulated under a wide range of true toxicity rates (from 0.05 to 0.70). The
following performance characteristics were considered:
•

Probability of weak evidence

•

Probability of favoring H1 under H1 , P( favors H1 | H1 ) , analogous to 1 − α

•

Probability of favoring H 2 under H 2 , P( favors H 2 | H 2 ) , analogous to 1 − β

The statistical properties were further compared using several cutoffs for the likelihood-ratio. We
highlight the results by presenting the benchmarks with the most distinctive behavior as far as
classifying the levels of evidence, i.e., k = 1, 2, and 8 . All simulation scenarios were conducted
with 10,000 trials each using the statistical software R (2009).
Numerous hypotheses ( p1 , p2 ) were tested and compared in terms of operating
characteristics. In this paper, we discuss four of the most interesting and relevant sets of
hypotheses. The values for the first two scenarios: (A) ( p1 = 0.40, p2 = 0.15) and

(B) ( p1 = 0.50, p2 = 0.10) were selected to be consistent with what is assumed regarding the
‘3+3’ design: it targets a DLT rate around 20-30%. These cases characterize situations when the
absolute difference between the hypotheses is greater than or equal to 30% with a midpoint close
to 30%. The other two scenarios: (C) ( p1 = 0.15, p2 = 0.05) and (D) ( p1 = 0.50, p2 = 0.30) were
selected to demonstrate the poor behavior of the ‘3+3’ design in selecting the MTD when both
hypotheses are either below or above a DLT rate of 0.20. These scenarios can be very well
encountered in practice. For agents where lethal or life threatening toxicities are expected (e.g.,
cytotoxic agents), investigators might be only willing to accept relatively low DLT rates.
Contrarily, the target DLT probability can be set high when toxicities are transient and nonfatal.
This may be the case for biologic agents used in immunotherapy, such as vaccines or adoptive
cell therapy, where a higher DLT rate (greater than 25-30%) might be considered tolerable.

4. Results
Levels of evidence
Tables 1 and 2 show the estimated likelihood ratios (LR) and the decisions regarding dose safety.
For each dose one of the following decisions can be made: “acceptable dose”, “toxic dose” or
“weak evidence”, i.e., not having enough evidence to conclude neither. Several benchmark
values of k were considered. However, we present the results for k = 1, 2, and 8 that mark a
significant change in the level of evidence. The scale of statistical evidence is not discrete, i.e.,
evidence does not suddenly move from one category to another. For example, for scenario (A)
benchmarks of 3, 4, and 5 generate the same conclusions as k = 2 regarding the strength of
evidence. The same stands for values of 7 and 8.

Table 1 illustrates scenarios (A) ( p1 = 0.40, p2 = 0.15) and (B) ( p1 = 0.50, p2 = 0.10) .
For k = 1 , the likelihood approach generates the same inferences as the ‘3+3” algorithm, by
favoring one of the two hypotheses (Table 1). For a threshold of 1, the weak evidence category is
eliminated. For k = 2 , the only weak evidence category is 2 DLTs out of 6 for scenario
(A) ( p1 = 0.40, p2 = 0.15) . Weak levels of evidence are common under k = 8 (Table 1). A cutoff
of 8 denotes fairly strong evidence and with cohorts of only 3 or 6 patients at a dose level we
expect weak evidence, especially when the difference between the hypotheses values is not very
large.
Table 2 displays scenarios (C) ( p1 = 0.15, p2 = 0.05) and (D) ( p1 = 0.50, p2 = 0.30) . For
scenario (C), the likelihood method disagrees with the ‘3+3’ algorithm only for 1 out of 6 DLTs
and k = 1. For k = 2 and k = 8, 1 out of 6 and 0 out of 3 DLTs are classified as weak evidence. In
the high toxicity scenario (D), 2 out of 6 DLTs are considered acceptable (k = 1). For k = 2, only
3 out of 6 DLTs are regarded as weak evidence, the rest being in good agreement with the ‘3+3’
rules. For k = 8 all categories are classified as weak evidence.

Operating characteristics
The operating characteristics of the likelihood method were further evaluated by computing the
following probabilities over a range of true DLT rates: P(weak evidence supporting neither
hypothesis), P( favors H1 | H1 ) , P( favors H 2 | H 2 ) , and comparing them to the operating
characteristics of the ‘3+3’ design. In figures 1 – 5, the solid lines mark the probabilities of
favoring H 2 - dose is acceptable (black) and favoring H1 - dose is unsafe (gray) generated by the
likelihood method. Using the same coloristic, the dashed lines represent the analogous
probabilities derived from the standard ‘3+3’ algorithm: probability of escalation - dose is

acceptable (black) and probability of non-escalation – dose is unsafe (gray). The gray dotted line
marks the level of weak evidence.
With a zero probability of weak evidence for k = 1, scenarios
(A) ( p1 = 0.40, p2 = 0.15) and (B) ( p1 = 0.50, p2 = 0.10) are in perfect agreement with the ‘3+3’
design (Figure 1A and 1B). For true DLT rates of 0.15 and 0.10, the probability of correctly
declaring the dose acceptable is of 81% and 88%, respectively, as shown by the height of the
black solid and dashed lines where they intersect the vertical line H 2 at 0.15 and 0.10 (Figure 1A
and 1B). When the true DLT rates are 0.40 and 0.50, the chances of correctly declaring the dose
unsafe are 69% and 82%, respectively, as shown by the height of the gray solid and dashed lines
where they intersect the vertical line H1 at 0.40 and 0.50 (Figure 1A and 1B).
For scenario (C) ( p1 = 0.15, p2 = 0.05) and k = 1, the algorithm has a higher probability of
correctly favoring H 2 (dose is acceptable) than the likelihood method (97% vs. 86%) at a true
DLT of 0.05, but a lower probability of correctly favoring H1 (dose is unsafe) (19% vs. 40% at
true DLT of 0.15) (Figure 1C). For the high toxicity scenario (D) ( p1 = 0.50, p2 = 0.30) , the
likelihood method performs better in declaring a dose acceptable (69% vs. 49% at true DLT of
0.30), but has almost 15% lower chances in identifying true toxicity when the DLT rate is 0.50
compared to the ‘3+3’ model (Figure 1D).
For k = 2, the probability of weak evidence steps away from zero for all scenarios but
(B) ( p1 = 0.50, p2 = 0.10) , which displays the same behavior as for k = 1 (Figure 2B). For
scenario (A) ( p1 = 0.40, p2 = 0.15) , the probability of weak evidence peaks at 19% between the
two hypotheses, represented in the figure by a dotted dark gray line. In this case, the likelihood
method and the ‘3+3’ algorithm match in correctly favoring H 2 (dose is acceptable) (Figure 2A).

Hypotheses (C) ( p1 = 0.15, p2 = 0.05) produce the highest probabilities of weak evidence for k =
2, i.e., 98% for a true DLT of 0.05 and 80% for a true DLT of 0.15 (Figure 2C). Surprisingly,
this probability is almost the same as the probability of escalation from the ‘3+3’ design. The
likelihood method and the algorithm correctly declare a dose unsafe with very similar
frequencies. For scenario (D) ( p1 = 0.50, p2 = 0.30) , the most notable difference in statistical
properties regards the probability of correctly favoring H1 . Hence, the likelihood method has
only an 18% chance of declaring the dose unsafe for a true DLT of 0.50, compared to 83% from
the ‘3+3’ algorithm (Figure 2D).
For k = 8, the probability of weak evidence is above 90% for both H1 and H 2 in
scenarios (A) ( p1 = 0.40, p2 = 0.15) and (D) ( p1 = 0.50, p2 = 0.30) (Figure 3A and 3D). The
likelihood method never favors H 2 (dose is acceptable) for all four sets of hypotheses and it has
a zero probability of declaring a dose unsafe for ( p1 = 0.50, p2 = 0.30) (Figure 3D). This
dramatic behavior of either always declaring a dose safe or unsafe when it is not the case can
have serious implications in a dose-finding trial. We caution against using a k threshold of 8, and
underline the small level of evidence that can be reached with only 6 patients per dose.
Since the category of weak evidence does not offer any clear guidance in making a
decision, it can easily be subject to interpretability. One option is to consider it as not having
enough information to conclude toxicity and to combine it with the evidence of favoring H 2
(safe dose). This is akin to “innocent until proven guilty”: we assume a dose is acceptably safe
until there is sufficient evidence to declare it unsafe. These results are displayed for all four sets
of hypotheses, k = 2 (Figure 4) and k = 8 (Figure 5). With this action, for k = 2, the likelihood
method and algorithm reach agreement for scenario (C) ( p1 = 0.15, p2 = 0.05) , but the probability

of identifying an unsafe dose remains low at 18% (Figure 4C). Moreover, for the high toxicity
hypotheses (D) ( p1 = 0.50, p2 = 0.30) , the combined probabilities of weak and correctly declaring
a dose safe increase to 92% for 0.15 true null DLT rate compared to 81% for k = 1 (Figure 4A).
For scenario (D), the probability of declaring a dose safe reaches almost 96% for the likelihood
method, but the performance of identifying toxicity is still poor (Figure 4D).

5. Discussion
In this paper we have explored the operating characteristics of the standard ‘3+3’ design in a
likelihood framework based on the evidential paradigm. We offer a probabilistic support for
analyzing its behavior for different sets of hypotheses, levels of evidence, and true (acceptable
and unacceptable) toxicity rates. Our likelihood approach has been developed to accommodate
any combination of those three, with R functions available upon request. This way, any
investigator (statistician or non-statistician) that intends to implement the standard algorithm has
the opportunity of testing its properties under different conditions and selecting the hypotheses
consistent with good performance characteristics at each dose level.
The evidential paradigm is an ideal setting for monitoring clinical trials with likelihood
inference. Compared to the Neyman-Pearson methodology, in this framework the strength of
evidence is quantified solely by the likelihood-ratio and it is amenable to sequential evaluation of
the data. Moreover, the strength of evidence is dissociated from the probability of observing
misleading evidence. In our simulation study we presented three likelihood-ratio thresholds: k =
1, 2, and 8. For the four sets of hypotheses considered, k = 8 is too stringent given the amount of
evidence generated from a maximum of 6 patients per dose. In this case, the probability of weak
evidence was over 80% and if combined with the probability of favoring H 2 it almost always

declared a dose safe even when it was truly toxic. The choice of k = 2 appears to be the most
reasonable one, generating operating characteristics in good agreement with the ‘3+3’ design.
This benchmark also produces high probabilities of correctly favoring H1 (dose is unsafe) and
correctly favoring H 2 (dose is acceptable). These high probabilities stand especially for sets of
hypotheses for which the unsafe DLT rate is greater than 0.30 and the acceptable DLT rate is less
than 0.20, with a midpoint around 30%. For more extreme scenarios: low ( p1 = 0.15, p2 = 0.05)
or high toxicity ( p1 = 0.50, p2 = 0.30) , both likelihood method and the ‘3+3’ design have less
than 20% probability of identifying a toxic dose. This means that for extreme scenarios the ‘3+3’
algorithm has no probabilistic support and it should not be used.
Our likelihood approach can be extended and implemented for cohorts of sizes other than
3 and 6. It is not uncommon for other cohort sizes to arise, either due to design or happenstance.
In those cases, there are not commonly used rules for declaring dose safe or unsafe. The
likelihood-ratio method with a fixed k and pre-stated hypotheses for the DLT rates allows
consistent inferences to be made and evidence to be quantified regardless of cohort size. Table 3
illustrates one of these situations with a cohort of 5 patients at a dose level. For
hypotheses ( p1 = 0.40, p2 = 0.15) and k = 2 as likelihood-ratio threshold, the method declares
toxicity for 2 or more DLTs. In the same manner, one can experiment with different cohort sizes
and k values and have a decision rule ready for any unexpected situation. In conclusion, our
approach offers great potential in both phase I designs for identifying the highest acceptably safe
dose and is akin to the sequential probability ratio test (Wald 1945).
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